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Abstract
The basic understanding of vascular dementia (VaD) and their molecular 
mechanisms are a too complex phenomenon. VaD associated neurodegeneration 
and cognitive impairment are due to multiple complications of the neurovascular 
system. The progress of VaD is due to the central and/or peripheral pathophysi-
ological process of the neurovascular system. There are limited nootropic agents are 
employed for the treatment of VaD. Moreover, the explored nootropic agents act on 
multiple targets such as receptors, enzymes, ion channel, free radicals, cytokines, 
chemokines, and apoptotic proteins. However, the enzyme targets, especially 
acetylcholinesterase inhibitors played a crucial role in the management of cognitive 
disorders. The pathogenesis of VaD is involved in the vascular complication and 
neurodegenerative process. Hence, the enzymatic regulation of neurovascular com-
plication is expected to prevent the VaD. The present chapter attempts to explore 
the recent advancement of enzyme targets for the management of VaD.
Keywords: cognitive dysfunction, enzymes, memory, neurodegeneration, 
neurovascular complication, vascular dementia
1. Introduction
Vascular dementia (VaD) is one of the leading factors for the changes in quality 
of life. It is declining the thinking ability [1]. The major etiology in the pathogenesis 
of VaD is blockage of cerebral blood vessels and/or reduction of regional and global 
cerebral blood flow [2]. This leads to depriving the brain cells for vital oxygen 
and energy by rising of free radicals; reduction of endogenous anti-oxidants and 
their regulatory enzymes [3]. The aging is another factor to develop neurovascular 
complications [4]. The developing country like India faces the serious complication 
of vascular dementia. India has more than 75 million populations older (above 60 
years) [5]. This age group; dramatically grow 7.5% of the population in every decade 
[6]. Therefore, demanding care for older people is growing day by day. The certain 
neurological disorders mainly occur in old age like dementia and Alzheimer’s 
disease (AD); however, the specialized medicines and improvements quality of 
life remains limited and challengeable [7]. Furthermore, VaD is mainly due to the 
various changes in vascular compartments in the brain. It is classified as cortical 
vascular dementia; subcortical ischemic dementia; strategic-infarct dementia; 
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hypoperfusion dementia; hemorrhagic dementia; and dementias of specific pathol-
ogy of cerebral artery [8]. The primary hallmark of the VaD is the development 
of cognitive deficits and impairment of functional abilities. The more specific 
diagnostic criteria for VaD described by Diagnostic Manual of Mental Disorders, 
4th edition (DMS-IV) criteria [9]; and National Institute of Neurological Disorders 
and Stroke—Association International pour le Recherché at L’Enseignement en 
Neurosciences (NINDS-AIREN) criteria [10]. The DSM-IV criteria have good 
sensitivity, but low specificity. Whereas the NINDS-AIREN criteria are the most 
specific to all available criteria and most commonly used in clinical research [11]. 
The clinical features of VaD are determined by the size, location, and type of cere-
bral damage. The classical clinical features of VaD are the abrupt onset of memory, 
stepwise deterioration of mental function, fluctuating learning course, abnormali-
ties of the motor and sensory response, gait changes and development of urinary 
incontinence [11].
Currently, the nootropic agents are used to treat the VaD [12]. Thus, the prescrip-
tion of nootropic agents such as central nervous system (CNS) stimulants (amphet-
amine, methylphenidate, caffeine and nicotine) [12]; Racetams [positive allosteric 
modulators of AMPA receptors and cholinergic systems such as piracetam, oxirace-
tam and aniracetam) [13, 14]; and miscellaneous such as L-theanine, tolcapone, 
levodopa, atomoxetine, Panax ginseng, Ginkgo biloba, Salvia officinalis [15], omega-3 
fatty acids, folate, vitamin B6, B12, and E [16, 17]; pramipexole, guanfacine clonidine, 
and fexofenadine are documented to produce the ameliorative effect in neurocogni-
tive disorders like vascular dementia [18, 19]. However, it produces the potential 
adverse effects and chronic usage it shown less efficacy [20]. Various nootropic 
agents are acts via multiple cellular targets like receptors, enzymes, ion channel, free 
radicals, cytokines, chemokines and apoptotic proteins [21]. However, the enzyme 
targets are shown to produce the better beneficial effects in neurocognitive disorders 
like acetylcholinesterase inhibitors carbamates (physostigmine, neostigmine, pyr-
idostigmine, ambenonium, demecarium, and rivastigmine) [22, 23]; phenanthrene 
derivatives (galantamine) [24]; donepezil; tacrine, edrophonium and huperzine A 
[25]. Therefore, this book chapter is focused to explore the role of enzymes in the 
pathogenesis of VaD and also discussed the recent advancement of enzymes targets 
based medicines for the management of VaD disorders.
2. Risk factors of vascular dementia
Globally, the aging peoples are suffering from dementia and AD and increase 
the burden to maintain the quality of life. The effective medicines for the treatment 
of VaD are not available and conventional nootropic medicines are relived the VaD 
symptomatically [26]. The factor medication for the pathogenesis of VaD is reducing 
the risk of cognitive decline effects. The main modifiable risk factors for VaD are lack 
of exercise, smoking, hypertension, obesity, diabetes mellitus, and chronic depres-
sion. The maintenance of this modifiable risk factors are supporting to prevents the 
pathogenesis of VaD and enhances the cognitive reserve function & quality of healthy 
life [27].
3. Characteristic features of VaD
The main characteristic features of VaD is described the problems of reason-
ing, planning, judgment, memory and thought processes. It occurs by damage 
central nervous system; and lack of cerebral blood circulation; and depriving of 
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the brain of vital oxygen and nutrients. Other than hyperglycemia, hyperten-
sion, hyper-lipidemia, and smoking; certain diseases also cause VaD like heart 
disease and stroke [28]. In the acute stage, confusion, trouble in attention; 
reduction of thinking ability; analyzing the ability of situation; deciding ability; 
restlessness; agitation; abnormal gait posture; frequent urination and/or inability 
to control the passing of urine; depression; and apathy. This characteristic feature 
of VaD develops the gradual manner like AD. The two main characteristic features 
are important for the pathogenesis of neurovascular disorders like VaD; one is 
arterial infarction (stroke) associated blocking of cerebral artery [28]. Some 
strokes are not producing noticeable symptoms of VaD. Whereas, it enhances the 
risk of VaD; and it is called multi-infarct dementia. Another feature of VaD is the 
chronic narrowness of cerebral blood vessels. It occurs by long-term damage of 
brain blood vessels by aging, high blood pressure, abnormal cholesterol deposi-
tion in the cerebral blood vessels, diabetes and brain hemorrhage [29]. These 
features are changes the wear and tear principles of cerebral blood vessels leads to 
cause the VaD.
4. Enzymes as a target for VaD
Various enzymes are identified in the regulation of neurovascular peptide action 
and it can prevent the cognitive disorders. Mainly drug target is focused on the 
receptors; ion channels; and nuclear proteins. There are limited drugs are explored 
in the enzymes based drug therapy for the neurovascular disorders [30]. Enzyme 
targeted medicines effectively prevent the various disorders such as inflammation 
(cyclooxygenase inhibitor); peptic ulcer (proton pump inhibitor); heart failure 
(sodium-potassium ATPase inhibitor); hypertension (angiotensin-converting 
enzyme inhibitor); depression (monoamino oxidase inhibitor); including memory 
disorder (acetylcholinesterase inhibitor). This chapter will open the “Pandora’s 
box” for the newer drug discovery for the treatment of VaD via enzyme inhibitors 
and modulators.
4.1 Acetylcholinesterase
Acetylcholinesterase (AChE; EC 3.1.1.7) also called as acetyl hydrolase. It 
belongs to carboxyl esterase family of enzymes. It predominantly acts on multiple 
organ systems including central as well as the peripheral nervous system [31]. The 
primary action of AChE is a breakdown of the acetylcholine to choline esters. In 
addition, it acts as neurotransmitters and alters the neuromuscular junctions and 
synaptic junctions. In addition, the central cholinergic system is plays a key role in 
the neuromodulatory action; vasomotor control; cerebral circulation of blood; and 
cognitive function. The basal prosencephalon and routes of their projections are 
the main areas for the cognitive function [32]. The vascular lesion of this area alters 
the cholinergic neuronal pathways via acetylcholinesterase and cholinergic neu-
rotransmitter action. The denervation of this cholinergic neuron plays a role in the 
development of cholinergic hypofunction and vascular dysfunction. Which leads 
to enhance the VaD associated cognitive dysfunction [32]. The administration of 
cholinesterase inhibitors like donepezil, galantamine and rivastigmine are symp-
tomatically relieved the symptoms of VaD in human [33]. Similarly, all three agents 
are shown beneficial effects in mild to the moderate condition of Alzheimer disease 
(AD) type of VaD. Even though, FDA has not approved the cholinesterase inhibitors 
for the treatment of advanced stages of the AD; due to lack of efficacy and tolerabil-
ity. Hence, some of the research reports suggest that cholinesterase inhibitors might 
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be useful for the other types of dementia like vascular dementia and dementia with 
Lewy bodies.
4.2 Amyloid-β-peptide alcohol dehydrogenase
ABAD (EC: 1.1.1.178) enzymes also belong from oxidoreductase enzyme. This 
alcohol dehydrogenase is activated by amyloid-β peptide and it affects cellular 
functions. The extracellular amyloid-β peptide is interacting with cell surface 
receptors and its trigger the intracellular signaling cascades. In addition, the 
amyloid-β peptide is interacting with specialized mitochondrial enzyme i.e., 
amyloid-β peptide-binding alcohol dehydrogenase (ABAD) [34]. The binding 
properties of the amyloid-β peptide to ABAD have altered the metabolic proper-
ties of the neuronal cell, and promotes mitochondrial free radicals synthesis via 
modulating the electron transport chain [35]. The activation of ABAD is required 
dinucleotide cofactor i.e., nicotinamide adenine dinucleotide (NADH). The over-
activation of ABAD enhance the amyloid-β rich environment leads to accelerates 
the cell stress leads to raising the levels of 4-hydroxynonenal-lysine; malondialde-
hyde-lysine; and induction of DNA fragmentation of the neurovascular system. In 
addition, ABAD induces the utilization of ketone bodies by neurovascular cells by 
promoting the conversion of acetyl-CoA to tricarboxylic acid cycle. This reaction 
also enhances the nutritional and/or metabolic stress [36]. The ABAD mutated 
(upregulated) transgenic mice are shown the amyloid-β peptide-rich environment 
leads to accelerates the spatial learning and memory impairment via cellular oxida-
tive stress [37]. Hence the Aβ and their target enzymes ABAD are contributed in 
the pathogenesis of neurovascular disorders including VaD. Therefore, the authors 
review the evidence that the prevention of Aβ binding to ABAD is a drug target for 
the treatment of AD. Therefore, the ABAD can be considered as a newer target for 
the attenuation of VaD.
4.3 Angiotensin-converting enzyme
Angiotensin-converting enzyme (ACE; EC: 3.4.17.23) is one of the families of 
hydrolase enzyme. ACE is a major component for the renin-angiotensin system (RAS). 
It plays a key role in the pathogenesis of blood pressure. ACE converts the angiotensin 
I (AT-I) to angiotensin II (AT-II). AT-II peptide is a potent endogenous vasoconstrictor. 
In addition, AT-II peptide and their receptor also play a various pathophysiological 
action on the central nervous system [38]. The brain-derived ACE has a role in the 
alteration of cerebral hemodynamics and execution of cognitive functions. Further, 
some literature revealed that anti-hypertensive medicines such as ACE inhibitors are 
shown the improvement of cognitive function via reduction of neurovascular damage. 
The inhibitor of centrally acting ACE enzymes like captopril, fosinopril, lisinopril, 
prinivil, perindopril, ramipril, and trandolapril is slow down the cognitive deterioration 
in human [39].
Furthermore, ACE interferes with bradykinin pathway in lung system and 
epithelial cells of the renal tissue. Currently, ACE is identified for the progress 
of neurodegenerative process via alteration of amyloid-β peptide metabolic and 
catabolic events. The treatment of ACE inhibitors is documented to produce the 
neuroprotection and prevention of neurodegenerative process [40]. The adminis-
tration of central acting ACE inhibitor i.e., captopril and perindopril are produced 
the ameliorative effect in late-onset AD type of VaD. Moreover, another ACE 
inhibitors i.e., enalapril and ramipril are also controlled the dementia-related cogni-
tive dysfunction [41]. Therefore, the ACE enzymes are playing a key target for the 
discovery of newer ACE inhibitors for VaD treatment.
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4.4 Endothelin-converting enzyme
Endothelin-converting enzyme (ECE) belongs from hydrolase family of 
enzyme and it is encoded by the ECE gene in human. The function of ECE 
is involved in the proteolysis process of endothelin peptides. There are three 
biologically active ECE are identified i.e., ECE-1; ECE-2; and ECE-3. The ECE-1 
are catalyzed the biologically active endothelin-1 (ET1); endothelin-2 (ET1); and 
endothelin-3 (ET1) peptides. The ECE-1 is primarily originated from endothelial 
cells; whereas, ECE-2 is originated from neuronal cells. Both ECEs have induced 
the ET-1 peptide production and cleavage the amyloid-β peptides [42]. The 
treatment of amyloid-β40 and amyloid-β42 peptides enhances the ECE-2 gene 
expression and release of ET-1 in neurovascular tissue. In addition, the endog-
enous superoxide dismutase prevents the amyloid-β40 induced release of ET-1. 
In AD patients, ECE1 induces the production of endothelin-1; and free radical is 
enhancing the cerebral vasoconstriction and reduction of cerebral blood flow. 
The chronic reduction of cerebral blood flow is one of the hallmarks in the patho-
genesis of VaD [43]. The ECE hydrolyzes the bioactive peptides like bradykinin, 
neurotensin, substance P and insulin B chain. In addition, the over-activation 
of ECEs are involved in the alteration of amyloid-β degradation. The ECE are 
altered the neurovascular function of various brain areas such as cerebral cor-
tex, hippocampus, amygdala, basal forebrain nuclei, diencephalon, brain stem, 
cerebellar hemisphere including hippocampus neurons. The clearance of amyloid 
β (Aβ) occurs by three major vasopeptidases i.e., neprilysin; ECE-1 and ECE-2. 
This clearance of amyloid β reactions occur by time; concentration and cellular 
environment dependent manner. And it accelerates the cellular metalloproteases 
enzymes leads to alter the vascular function and enhances the pathogenesis of 
VaD [44].
In addition, the non-selective dual endothelin-A (ET-A) and ET-B receptor 
antagonist i.e., bosentan ameliorates diabetes induced vascular endothelial dysfunc-
tion and vascular dementia in rats [45]. Similarly, it also attenuates the hyperhomo-
cysteinemia, β-amyloid and renovascular hypertension-induced vascular dementia 
in rats. Further, the administration of selective endothelin ET-A receptor antagonist 
i.e., ambrisentan attenuates the L-methionine-induced vascular dementia in rats 
[46]. ECEs inhibitors can control the accumulation of ET-1 peptide and activation 
of ET receptors. Therefore, ECE regulators, especially ECE-1 can be a key target for 
the management of VaD.
4.5 Histone deacetylase
Histone deacetylase (HDAC; EC: 3.5.1.98) is belonging from the hydrolases type 
of enzymes. HDAC removes the acetyl groups (O〓C▬CH3) from ε-N-acetyl lysine 
amino acid of the histone proteins. And, it makes the tight wrapping of DNA to 
histone proteins [47]. This process supports the regulation of DNA expression via 
the cyclic action of acetylation and de-acetylation events. Histone acetyltransferase 
is opposite the histone deacetylase action. In addition, lysine deacetylases (KDAC) 
enzymes are similar to that of HDAC action; but it also produces the non-histone 
protein-mediated DNA expression actions. The primary action of HDAC action is 
a modification of histone tails via modification of lysine and arginine amino acids. 
These changes make the positive charges environment on histone tails and interact 
negatively charged phosphate groups of DNA backbone [48]. Acetylation process 
is neutralizing the positive charges of the histone tail leads to decreases the DNA 
interactions. In this case, histone proteins allow the chromatin expansion; permits 
the gene transcription. In a paradox, HDAC opposite this all reaction sequences. In a 
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normal cell, HDAC is regulated the cellular processes via cell growth; cellular apop-
tosis; and cell cycle events. In pathological conditions, it stimulates the cancer cell 
growth; and actives the chronic myeloid leukemia progress. The hyperacetylation of 
chromatin is causing the abnormal transcription process [49].
There are 18 numbers of HDACs are identified in human i.e., HDAC1 to HDAC18. 
It is further divided into four classes i.e., class I: Rpd3-like proteins (HDAC1–3; and 
HDAC8); class II: Hda1-like proteins (HDAC4–7; HDAC9; and HDAC10); class III: 
Sir2-like proteins (SIRT1–7); and class IV protein (HDAC11) [50]. HDAC inhibitor-
like valproic acid is used for psychiatric disorders including epileptic disorders. 
Another, HDAC inhibitors i.e., vorinostat and romidepsin are approved for the 
treatment of cutaneous T cell lymphoma [51]. Trichostatin A (potent HDAC inhibi-
tors) are used for neurovascular disorders like stroke; AD; and VaD. The non-selec-
tive inhibitor of HDACs i.e., sodium butyrate attenuates the heavy metal i.e., arsenic 
metal; and streptozotocin-induced endothelial dysfunction and VaD in rats [52]. 
Currently, the administration of sodium butyrate also ameliorates the ischemia-
induced vascular dysfunction in aged female rats [53]. Various HDAC inhibitors are 
documented to produce the neuroprotection against multiple and variable type of 
brain injury such agents are suberoylanilide hydroxamic acid (SAHA); hydroxamic 
acid derivatives (ITF2357); valproic acid (VPA); trichostatin A (TSA); sodium 
4-phenylbutyrate (4-PBA); 4-dimethylamino-N-[5-(2-mercaptoacetylamino)pen-
tyl]benzamide (DMA) [54]. However, the effect of these agents in the management 
Figure 1. 
This illustration revealed that, the role of neurovascular enzyme alteration for the alteration neurovascular 
dysfunction; neurodegeneration; neuronal death; and vascular dysfunction associated with vascular dementia. 
Abbreviations: AChE, acetylcholinesterase; ABAD, amyloid-β-peptide alcohol dehydrogenase; ACE, 
angiotensin converting-enzyme; CART, carnitine acetyltransferase; ECE, endothelin-converting enzyme-1; 
NOX, nicotinamide adenine dinucleotide phosphate oxidase; and HDAC, histone deacetylases.
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of VaD and endothelial dysfunction is not explored yet. HDAC inhibitors are 
identified as neurovascular protective agents and prevention of VaD. Hence, HDAC 
inhibitors need to explore in the management of VaD disorders. The role of neu-
rovascular enzyme targets and their mechanism for the alteration neurovascular 
dysfunction; neurodegeneration; neuronal death; and vascular dysfunction associ-
ated vascular dementia is illustrated in Figure 1.
5. Future perspectives
Based on the available literature, it concluded that enzymes targets can treat the 
neurovascular disorders via prevention of endothelial dysfunction; neuroprotec-
tion; enhancement of neuronal plasticity; and anti-apoptotic action. In addition, 
these enzymes targets are also regulated the neuronal as well as vascular growth fac-
tor via epigenetic modification and controlling of pre and post-translational protein 
modifications. Functionally, these enzymes modulators are improved the neurocog-
nitive functions in AD, PD, stroke conditions including VaD in animals as well as 
in patients. Currently, the various enzymes are identified their roles; physiological 
& pathological functions; involvements in the neurovascular system; identifica-
tion of endogenous and exogenous substrates; and their modulators. However, the 
limited enzyme modulators only tested in animals. Still need more discoveries to 
develop the enzymes modulators for the above enzymes targets with their specific-
ity, potency and enhanced functionality. Thus, this book chapter will help to the 
audience to open the “Pandora’s box” for the discovery of novel enzyme targets and 
modulators for the treatment of neurovascular disorders.
6. Conclusion
Based on this review of the literature, it is concluded that the pathogenesis of 
VaD is occurred by multiple pathophysiological events. However, literature shown 
that enzymes targets are contributed the development of neurovascular disorders 
such as VaD. The chronic progress of vascular dysfunction makes the neuronal 
death; neurodegeneration and cognitive impairment. This book chapter section also 
showed the evidence of enzymes modulators for the treatment of VaD. However, 
the specific modulator of this enzymes targeted action is needed to investigate in 
different pathophysiological conditions of VaD. Further, it also needs to study in 
clinically relevant animal models and in human subjects.
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